Lum SHan, James B, Ottaviano G, Ewins A-M, Patrick K, Ali S, Carpenter B, Silva J, Tewari S, Furness C, et al. Alemtuzumab, dual GVHD prophylaxis, and lower CD3+ T cell doses equalize rates of acute and chronic GVHD among pediatric patients receiving allogeneic HSCT with matched unrelated donor PBSC or bone marrow grafts. Transplant Cell Ther. 2023.